ROTHBLATT MARTINE A sold $5.2M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $549.37 ($542.06–$574.22, $5.22M total) across 23 trades on 2026-10-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds new information about insider activity, but its modest size limits trading relevance.
Market read
Provides fresh insider‑sell data; limited impact on price due to small transaction size.
What to watch
Potential upcoming clinical data or financing events could offset the sell‑off pressure.
Background
Form 4 filing from United Therapeutics Corp discloses a 10b5‑1 sale by its CEO.
Ticker impact
CEO and Chairperson Martine A. Rothblatt sold 9,500 shares for $5.2 M via a pre‑arranged 10b5‑1 plan, reducing her stake to 324,443 shares.
likely slight pressure as the market prices in the insider sell
A $5 M sale by the CEO is material for a micro‑cap biotech, but the amount is modest relative to market cap, so impact is limited.
Market effects
Minimal; biotech sector not broadly affected by a single insider sale.
None; company is US‑listed with limited regional exposure.
Low; no broader market implications.
Counterpoint
The sale could be a routine liquidity event unrelated to fundamentals, so price may remain stable.
Key entities
- companyUnited Therapeutics Corp
US‑listed biotech firm (ticker UTHR).
- personMartine A. Rothblatt
Chairperson & CEO of United Therapeutics.
